Verona Pharma plc Verona Pharma To Present At Cowen And Company 39th Annual Health Care Conference
February 28 2019 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(NASDAQ: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, today announces that the Company's management
team will present and conduct face-to-face meetings at the Cowen and
Company 39(th) Annual Health Care Conference.
Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present
on Wednesday, March 13th at 10:00 am ET. A webcast of the presentation
will be available on the "events and presentation" page of the
"investors" section of Verona Pharma's website. For more information,
please visit
https://www.globenewswire.com/Tracker?data=3kb5CVi1oSyO4Y4EDgucORYSm7aTFgIZkq8PixHe-tulqUc1kz37QtXTYErLvJCF2vgonq-6wwTZdaCPemnt7AjjrUbsxYlVqN39hCX_lLGfRwdXM-C5EGo0nvKi1McW
investors.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine, is an investigational
first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase
3 and 4 that is designed to act as both a bronchodilator and an
anti-inflammatory agent in a single compound. In previous clinical
trials, the nebulized formulation of ensifentrine has been observed to
result in bronchodilator effects when used alone or as an add-on
treatment to other COPD bronchodilators. It has shown clinically
meaningful and statistically significant improvements in lung function
when administered in addition to frequently used short- and long-acting
bronchodilators, such as tiotropium (Spiriva(R) ), compared with such
bronchodilators administered as a single agent. Ensifentrine improved
FEV(1) over four weeks in patients with moderate-to-severe COPD when
compared to placebo and improved COPD symptoms and quality of life in a
Phase 2b multicenter European study performed in 403 patients. In
addition, ensifentrine has shown anti-inflammatory effects in a standard
challenge study with COPD-like inflammation in human subjects.
Ensifentrine has been well tolerated in these studies, having been
administered to more than 800 subjects in 13 clinical trials. Verona
Pharma is developing ensifentrine for the treatment of COPD, CF, and
asthma.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, statements that there is an opportunity
for additional bronchodilator and symptomatic improvement via the novel
mechanism of action of ensifentrine and Verona Pharma's plans to carry
out further long-term clinical studies of ensifentrine as an add-on to
both single and dual bronchodilator therapy and the expectation that
even more profound anti-inflammatory effects, leading to improvements in
lung function, as well as improvements in symptoms will result.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of RPL554, which
may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of RPL554, our only product candidate under
development; economic, political, regulatory and other risks involved
with international operations; the lengthy and expensive process of
clinical drug development, which has an uncertain outcome; serious
adverse, undesirable or unacceptable side effects associated with
RPL554, which could adversely affect our ability to develop or
commercialize RPL554; potential delays in enrolling patients, which
could adversely affect our research and development efforts; we may not
be successful in developing RPL554 for multiple indications; our ability
to obtain approval for and commercialize RPL554 in multiple major
pharmaceutical markets; misconduct or other improper activities by our
employees, consultants, principal investigators, and third-party service
providers; material differences between our "top-line" data and final
data; our reliance on third parties, including clinical investigators,
manufacturers and suppliers, and the risks related to these parties'
ability to successfully develop and commercialize RPL554; and lawsuits
related to patents covering RPL554 and the potential for our patents to
be found invalid or unenforceable. These and other important factors
under the caption "Risk Factors" in our Annual Report on Form 20-F filed
with the Securities and Exchange Commission ("SEC") on February 27,
2018, and our other reports filed with the SEC, could cause actual
results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking statements at
some point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
February 28, 2019 02:00 ET (07:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024